MARKET

APLM

APLM

APOLLOMICS INC
NASDAQ
20.80
-1.20
-5.45%
After Hours: 20.39 -0.41 -1.97% 16:36 06/26 EDT
OPEN
20.00
PREV CLOSE
22.00
HIGH
21.73
LOW
19.93
VOLUME
32.41K
TURNOVER
--
52 WEEK HIGH
42.12
52 WEEK LOW
3.659
MARKET CAP
45.68M
P/E (TTM)
-2.7495
1D
5D
1M
3M
1Y
5Y
1D
Apollomics Inc trading resumes
TipRanks · 2d ago
Apollomics Inc trading halted, volatility trading pause
TipRanks · 2d ago
Apollomics Terminates License Agreement With Launxp International
Dow Jones · 2d ago
Apollomics initiates dispute process with Launxp over unpaid $3.8 million vebreltinib license fee
PUBT · 2d ago
APOLLOMICS: FORMALLY INITIATED DISPUTE RESOLUTION PROCESS ON JUNE 18 RELATED TOP LAUNXP INTERNATIONAL AGREEMENT TERMINATION
Reuters · 2d ago
Apollomics receives noncompliance notice from Nasdaq
TipRanks · 2d ago
Apollomics Receives Nasdaq Noncompliance Notice, Gets Time Through Dec. 15 To Regain Compliance; Terminates Agreement With Launxp International Due To Latter's Failure To Cure Material Breach Obligations Over Remaining $3.8M Upfront Payment
Benzinga · 2d ago
APOLLOMICS - REGAINS RIGHTS TO VEBRELTINIB (APL-101) IN ASIA
Reuters · 2d ago
More
About APLM
Apollomics Inc. is a clinical-stage biopharmaceutical company focusing on discovering and developing oncology therapies to address unmet medical needs, especially for difficult-to-treat and treatment-resistant cancers. The product candidates in its pipeline are categorized into two groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumor inhibitors and immuno-oncology drugs. Its tumor inhibitor product candidates consist of three small-molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells: vebreltinib, APL-102 and APL-122. Its three immuno-oncology product candidates consist of APL-501, APL-502 and APL-80. Vebreltinib is a potent, oral active selective c-Met inhibitor. APL-102 is an oral active, small molecule Multiple Tyrosine Kinase Inhibitor. APL-122 is a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways. APL-501 is an anti-PD-1 antibody product candidate.

Webull offers Apollomics Inc stock information, including NASDAQ: APLM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APLM stock methods without spending real money on the virtual paper trading platform.